First Report of the Prevalence at Baseline and after 1-Year Follow-Up of Treatable Traits in Interstitial Lung Diseases

Different factors, not limited to the lung, influence the progression of ILDs. A “treatable trait” strategy was recently proposed for ILD patients as a precision model of care to improve outcomes. However, no data have been published so far on the prevalence of TTs in ILD. A prospective, observation...

Full description

Saved in:

Bibliographic Details
Published in:	Biomedicines Vol. 12; no. 5; p. 1047
Main Authors:	Amati, Francesco, Stainer, Anna, Maruca, Giacomo, De Santis, Maria, Mangiameli, Giuseppe, Torrisi, Chiara, Bossi, Paola, Polelli, Veronica, Blasi, Francesco, Selmi, Carlo, Marulli, Giuseppe, Balzarini, Luca, Terracciano, Luigi Maria, Gatti, Roberto, Aliberti, Stefano
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 01.05.2024
Subjects:	Airway management Asthma Cardiology Chronic obstructive pulmonary disease Clinical outcomes Comorbidity Connective tissue diseases Cough Development and progression Emphysema endotypes Genotype & phenotype interstitial lung diseases Kinases Lung diseases Medical prognosis Patients Pharmaceutical industry phenotypes Population studies Precision medicine Quality of life Respiratory diseases Respiratory failure Sarcoidosis treatable traits Treprostinil Germany endotypes treatable traits phenotypes interstitial lung diseases
ISSN:	2227-9059, 2227-9059
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Different factors, not limited to the lung, influence the progression of ILDs. A “treatable trait” strategy was recently proposed for ILD patients as a precision model of care to improve outcomes. However, no data have been published so far on the prevalence of TTs in ILD. A prospective, observational, cohort study was conducted within the ILD Program at the IRCCS Humanitas Research Hospital (Milan, Italy) between November 2021 and November 2023. TTs were selected according to recent literature and assigned during multidisciplinary discussion (MDD) to one of the following categories: pulmonary, etiological, comorbidities, and lifestyle. Patients were further divided into four groups according to their post-MDD diagnosis: idiopathic ILD, sarcoidosis, connective tissue disease–ILD, and other ILD. The primary study outcome was the prevalence of each TT in the study population. A total of 116 patients with ILD [63.9% male; median (IQR) age: 69 (54–78) years] were included in the study. All the TTs identified in the literature were found in our cohort, except for intractable chronic cough. We also recognized differences in TTs across the ILD groups, with less TTs in patients with sarcoidosis. This analysis provides the first ancillary characterization of TTs in ILD patients in a real setting to date.
AbstractList	Different factors, not limited to the lung, influence the progression of ILDs. A “treatable trait” strategy was recently proposed for ILD patients as a precision model of care to improve outcomes. However, no data have been published so far on the prevalence of TTs in ILD. A prospective, observational, cohort study was conducted within the ILD Program at the IRCCS Humanitas Research Hospital (Milan, Italy) between November 2021 and November 2023. TTs were selected according to recent literature and assigned during multidisciplinary discussion (MDD) to one of the following categories: pulmonary, etiological, comorbidities, and lifestyle. Patients were further divided into four groups according to their post-MDD diagnosis: idiopathic ILD, sarcoidosis, connective tissue disease–ILD, and other ILD. The primary study outcome was the prevalence of each TT in the study population. A total of 116 patients with ILD [63.9% male; median (IQR) age: 69 (54–78) years] were included in the study. All the TTs identified in the literature were found in our cohort, except for intractable chronic cough. We also recognized differences in TTs across the ILD groups, with less TTs in patients with sarcoidosis. This analysis provides the first ancillary characterization of TTs in ILD patients in a real setting to date. Different factors, not limited to the lung, influence the progression of ILDs. A "treatable trait" strategy was recently proposed for ILD patients as a precision model of care to improve outcomes. However, no data have been published so far on the prevalence of TTs in ILD. A prospective, observational, cohort study was conducted within the ILD Program at the IRCCS Humanitas Research Hospital (Milan, Italy) between November 2021 and November 2023. TTs were selected according to recent literature and assigned during multidisciplinary discussion (MDD) to one of the following categories: pulmonary, etiological, comorbidities, and lifestyle. Patients were further divided into four groups according to their post-MDD diagnosis: idiopathic ILD, sarcoidosis, connective tissue disease-ILD, and other ILD. The primary study outcome was the prevalence of each TT in the study population. A total of 116 patients with ILD [63.9% male; median (IQR) age: 69 (54-78) years] were included in the study. All the TTs identified in the literature were found in our cohort, except for intractable chronic cough. We also recognized differences in TTs across the ILD groups, with less TTs in patients with sarcoidosis. This analysis provides the first ancillary characterization of TTs in ILD patients in a real setting to date.Different factors, not limited to the lung, influence the progression of ILDs. A "treatable trait" strategy was recently proposed for ILD patients as a precision model of care to improve outcomes. However, no data have been published so far on the prevalence of TTs in ILD. A prospective, observational, cohort study was conducted within the ILD Program at the IRCCS Humanitas Research Hospital (Milan, Italy) between November 2021 and November 2023. TTs were selected according to recent literature and assigned during multidisciplinary discussion (MDD) to one of the following categories: pulmonary, etiological, comorbidities, and lifestyle. Patients were further divided into four groups according to their post-MDD diagnosis: idiopathic ILD, sarcoidosis, connective tissue disease-ILD, and other ILD. The primary study outcome was the prevalence of each TT in the study population. A total of 116 patients with ILD [63.9% male; median (IQR) age: 69 (54-78) years] were included in the study. All the TTs identified in the literature were found in our cohort, except for intractable chronic cough. We also recognized differences in TTs across the ILD groups, with less TTs in patients with sarcoidosis. This analysis provides the first ancillary characterization of TTs in ILD patients in a real setting to date.
Audience	Academic
Author	Polelli, Veronica Balzarini, Luca Gatti, Roberto Maruca, Giacomo Marulli, Giuseppe Terracciano, Luigi Maria Bossi, Paola Amati, Francesco Torrisi, Chiara De Santis, Maria Selmi, Carlo Blasi, Francesco Mangiameli, Giuseppe Stainer, Anna Aliberti, Stefano
Author_xml	– sequence: 1 givenname: Francesco orcidid: 0000-0002-8248-7785 surname: Amati fullname: Amati, Francesco – sequence: 2 givenname: Anna surname: Stainer fullname: Stainer, Anna – sequence: 3 givenname: Giacomo surname: Maruca fullname: Maruca, Giacomo – sequence: 4 givenname: Maria orcidid: 0000-0002-3196-1336 surname: De Santis fullname: De Santis, Maria – sequence: 5 givenname: Giuseppe surname: Mangiameli fullname: Mangiameli, Giuseppe – sequence: 6 givenname: Chiara orcidid: 0009-0007-5767-665X surname: Torrisi fullname: Torrisi, Chiara – sequence: 7 givenname: Paola surname: Bossi fullname: Bossi, Paola – sequence: 8 givenname: Veronica surname: Polelli fullname: Polelli, Veronica – sequence: 9 givenname: Francesco orcidid: 0000-0002-2285-9970 surname: Blasi fullname: Blasi, Francesco – sequence: 10 givenname: Carlo orcidid: 0000-0002-0323-0376 surname: Selmi fullname: Selmi, Carlo – sequence: 11 givenname: Giuseppe surname: Marulli fullname: Marulli, Giuseppe – sequence: 12 givenname: Luca surname: Balzarini fullname: Balzarini, Luca – sequence: 13 givenname: Luigi Maria surname: Terracciano fullname: Terracciano, Luigi Maria – sequence: 14 givenname: Roberto surname: Gatti fullname: Gatti, Roberto – sequence: 15 givenname: Stefano surname: Aliberti fullname: Aliberti, Stefano
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/38791009$$D View this record in MEDLINE/PubMed
BookMark	eNp9kt9vFCEQxzemxtba_8AYEl982QoLuyy-tbWnl1yiMe2DT2RgZ08ue3ACZ-N_X85r_dE0wgMD-Xy_kxnmeXXgg8eqesnoKeeKvjUurHFw1nlMrKEto0I-qY6appG1oq06-Cs-rE5SWtGyFOM9E8-qQ95Lxcr9qLqZuZgy-YKbEDMJI8nfkHyO-AMm9BYJZHIOCaeSiIAfCIwZI2H1V4RIZmGawk19vdkJryJCBjNhicDlRJwnc1_olF12MJHF1i_Je5ew-KUX1dMRpoQnd-dxdT27vLr4WC8-fZhfnC1q2zKRa4M9jKxnlquetxIYdICDNWj6jg-mp0B7HDrDjeTUqo7LruGqEVYqhWrk_Lia732HACu9iW4N8acO4PSvhxCXGmJ2dkINbBxKU4TE3ghOGRjetbyRhhohG8GK15u91yaG71tMWa9dsjhN4DFsk-a0o1zyttmhrx-gq7CNvlRaqFYJKnin_lDL0m3t_BhyBLsz1WdStbynom0LdfoIVfaAa2fLXIyuvP8jeHWXfGvKlPyu-v7XC_BuD9gYUoo4ausyZBd8cXaTZlTvpkw_NmVFLB6I7_3_K7sFE2nWNA
CitedBy_id	crossref_primary_10_1016_j_rmed_2025_108333 crossref_primary_10_1177_17534666251342661 crossref_primary_10_3390_ph18030411 crossref_primary_10_3390_biomedicines13071529
Cites_doi	10.1183/23120541.00316-2021 10.1164/rccm.201807-1255ST 10.1183/13993003.02058-2018 10.1183/16000617.0340-2020 10.1186/s12931-020-01432-x 10.1164/rccm.202206-1041ST 10.1385/CRIAI:25:2:115 10.1164/rccm.202306-1113ST 10.1016/j.chest.2021.02.026 10.1136/thoraxjnl-2012-202646 10.1016/j.chest.2021.03.066 10.1016/S2213-2600(23)00093-0 10.1183/13993003.00404-2023 10.1016/S2213-2600(23)00002-4 10.1183/13993003.01359-2015 10.1183/23120541.00597-2021 10.1148/radiology.209.3.9844661 10.1164/rccm.201308-1483ST 10.1183/16000617.0169-2021 10.1183/13993003.01509-2019 10.1056/NEJMoa1908681 10.1111/resp.14325 10.1186/s12931-023-02554-8 10.1186/s12931-019-1022-1 10.1164/rccm.202202-0399ST 10.3390/jcm9041081 10.1016/j.envint.2019.104934 10.1056/NEJMoa2008470
ContentType	Journal Article
Copyright	COPYRIGHT 2024 MDPI AG 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: COPYRIGHT 2024 MDPI AG – notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	AAYXX CITATION NPM 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M7P PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 DOA
DOI	10.3390/biomedicines12051047
DatabaseName	CrossRef PubMed ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea ProQuest Central Student SciTech Premium Collection ProQuest Biological Science Collection Biological Science Database ProQuest Databases ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Biological Science Collection ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection Biological Science Database ProQuest SciTech Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Academic UKI Edition Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic
DatabaseTitleList	CrossRef MEDLINE - Academic PubMed Publicly Available Content Database
Database_xml	– sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Engineering
EISSN	2227-9059
ExternalDocumentID	oai_doaj_org_article_a1fd10047e8b4301ab365327b0b47241 A795380455 38791009 10_3390_biomedicines12051047
Genre	Journal Article
GeographicLocations	Germany
GeographicLocations_xml	– name: Germany
GroupedDBID	53G 5VS 8FE 8FH AADQD AAFWJ AAYXX ACPRK ADBBV AFFHD AFKRA AFPKN AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI CCPQU CITATION EMOBN GROUPED_DOAJ GX1 HCIFZ HYE IAO IHR INH ITC KQ8 LK8 M7P MODMG M~E OK1 PGMZT PHGZM PHGZT PIMPY PQGLB PROAC RPM NPM ABUWG AZQEC DWQXO GNUQQ PKEHL PQEST PQQKQ PQUKI PRINS 7X8 PUEGO
ID	FETCH-LOGICAL-c514t-be8af181c398357a1a6aedcbeb863db80a08ed6b3b730c9637623924c799e9f33
IEDL.DBID	DOA
ISICitedReferencesCount	5
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001232395300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2227-9059
IngestDate	Tue Oct 14 19:05:01 EDT 2025 Wed Oct 01 14:42:37 EDT 2025 Fri Jul 25 11:53:52 EDT 2025 Tue Nov 11 11:05:19 EST 2025 Tue Nov 04 18:24:17 EST 2025 Thu Jan 02 22:34:42 EST 2025 Tue Nov 18 22:00:00 EST 2025 Sat Nov 29 07:11:12 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Keywords	endotypes treatable traits phenotypes interstitial lung diseases
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c514t-be8af181c398357a1a6aedcbeb863db80a08ed6b3b730c9637623924c799e9f33
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0002-0323-0376 0000-0002-3196-1336 0000-0002-2285-9970 0009-0007-5767-665X 0000-0002-8248-7785
OpenAccessLink	https://doaj.org/article/a1fd10047e8b4301ab365327b0b47241
PMID	38791009
PQID	3059404369
PQPubID	2032426
ParticipantIDs	doaj_primary_oai_doaj_org_article_a1fd10047e8b4301ab365327b0b47241 proquest_miscellaneous_3060373521 proquest_journals_3059404369 gale_infotracmisc_A795380455 gale_infotracacademiconefile_A795380455 pubmed_primary_38791009 crossref_citationtrail_10_3390_biomedicines12051047 crossref_primary_10_3390_biomedicines12051047
PublicationCentury	2000
PublicationDate	2024-05-01
PublicationDateYYYYMMDD	2024-05-01
PublicationDate_xml	– month: 05 year: 2024 text: 2024-05-01 day: 01
PublicationDecade	2020
PublicationPlace	Switzerland
PublicationPlace_xml	– name: Switzerland – name: Basel
PublicationTitle	Biomedicines
PublicationTitleAlternate	Biomedicines
PublicationYear	2024
Publisher	MDPI AG
Publisher_xml	– name: MDPI AG
References	McDonald (ref_13) 2020; 55 Hilberg (ref_19) 2022; 8 Ward (ref_25) 2010; 39 Cottin (ref_18) 2022; 206 Raghu (ref_16) 2018; 198 Zantah (ref_21) 2020; 21 Hamblin (ref_2) 2022; 31 Travis (ref_17) 2021; 160 Travis (ref_1) 2013; 188 Laohaburanakit (ref_23) 2003; 25 McDonald (ref_27) 2013; 68 Raghu (ref_28) 2022; 205 McDonald (ref_11) 2019; 53 Raghu (ref_29) 2024; 209 Chalmers (ref_15) 2023; 11 Rapsomaniki (ref_14) 2022; 27 Zhao (ref_20) 2021; 7 Chen (ref_26) 2019; 130 ref_24 Vonk (ref_5) 2021; 30 Kolb (ref_3) 2019; 20 Flaherty (ref_6) 2019; 381 Agusti (ref_12) 2016; 47 Hansell (ref_22) 1998; 209 Amati (ref_9) 2023; 24 Khor (ref_10) 2023; 62 Waxman (ref_7) 2021; 384 Lee (ref_4) 2021; 160 Amati (ref_8) 2023; 11
References_xml	– volume: 7 start-page: 00316 year: 2021 ident: ref_20 article-title: Mortality in combined pulmonary fibrosis and emphysema patients is determined by the sum of pulmonary fibrosis and emphysema publication-title: ERJ Open Res. doi: 10.1183/23120541.00316-2021 – volume: 198 start-page: e44 year: 2018 ident: ref_16 article-title: Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline publication-title: Am. J. Respir. Crit. Care Med. doi: 10.1164/rccm.201807-1255ST – volume: 53 start-page: 1802058 year: 2019 ident: ref_11 article-title: Treatable Traits: A new paradigm for 21st century management of chronic airway diseases publication-title: Eur. Respir. J. doi: 10.1183/13993003.02058-2018 – volume: 39 start-page: 106 year: 2010 ident: ref_25 article-title: Interstitial lung disease—An approach to diagnosis and management publication-title: Aust. Fam. Physician – volume: 30 start-page: 200340 year: 2021 ident: ref_5 article-title: Natural variability in the disease course of SSc-ILD: Implications for treatment publication-title: Eur. Respir. Rev. doi: 10.1183/16000617.0340-2020 – volume: 21 start-page: 164 year: 2020 ident: ref_21 article-title: Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema publication-title: Respir. Res. doi: 10.1186/s12931-020-01432-x – volume: 206 start-page: e7 year: 2022 ident: ref_18 article-title: Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement publication-title: Am. J. Respir. Crit. Care Med. doi: 10.1164/rccm.202206-1041ST – volume: 25 start-page: 115 year: 2003 ident: ref_23 article-title: Obstructive sarcoidosis publication-title: Clin. Rev. Allergy Immunol. doi: 10.1385/CRIAI:25:2:115 – volume: 209 start-page: 137 year: 2024 ident: ref_29 article-title: Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline publication-title: Am. J. Respir. Crit. Care Med. doi: 10.1164/rccm.202306-1113ST – volume: 160 start-page: 209 year: 2021 ident: ref_4 article-title: Characteristics and Prevalence of Domestic and Occupational Inhalational Exposures Across Interstitial Lung Diseases publication-title: Chest doi: 10.1016/j.chest.2021.02.026 – volume: 68 start-page: 691 year: 2013 ident: ref_27 article-title: Multidimensional assessment and tailored interventions for COPD: Respiratory utopia or common sense? publication-title: Thorax doi: 10.1136/thoraxjnl-2012-202646 – volume: 160 start-page: e97 year: 2021 ident: ref_17 article-title: Diagnosis and Evaluation of Hypersensitivity Pneumonitis: CHEST Guideline and Expert Panel Report publication-title: Chest doi: 10.1016/j.chest.2021.03.066 – volume: 11 start-page: 637 year: 2023 ident: ref_15 article-title: Bronchiectasis in Europe: Data on disease characteristics from the European Bronchiectasis registry (EMBARC) publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(23)00093-0 – volume: 62 start-page: 2300404 year: 2023 ident: ref_10 article-title: Treatable traits: A comprehensive precision medicine approach in interstitial lung disease publication-title: Eur. Respir. J. doi: 10.1183/13993003.00404-2023 – volume: 11 start-page: 125 year: 2023 ident: ref_8 article-title: Treatable traits in interstitial lung diseases: A call to action publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(23)00002-4 – volume: 47 start-page: 410 year: 2016 ident: ref_12 article-title: Treatable traits: Toward precision medicine of chronic airway diseases publication-title: Eur. Respir. J. doi: 10.1183/13993003.01359-2015 – volume: 8 start-page: 00597 year: 2022 ident: ref_19 article-title: Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries publication-title: ERJ Open Res. doi: 10.1183/23120541.00597-2021 – volume: 209 start-page: 697 year: 1998 ident: ref_22 article-title: Pulmonary sarcoidosis: Morphologic asociations of airflow obstruction at thin-section CT publication-title: Radiology doi: 10.1148/radiology.209.3.9844661 – volume: 188 start-page: 733 year: 2013 ident: ref_1 article-title: An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias publication-title: Am. J. Respir. Crit. Care Med. doi: 10.1164/rccm.201308-1483ST – volume: 31 start-page: 210169 year: 2022 ident: ref_2 article-title: Diagnosis, course and management of hypersensitivity pneumonitis publication-title: Eur. Respir. Rev. doi: 10.1183/16000617.0169-2021 – volume: 55 start-page: 1901509 year: 2020 ident: ref_13 article-title: Targeting treatable traits in severe asthma: A randomised controlled trial publication-title: Eur. Respir. J. doi: 10.1183/13993003.01509-2019 – volume: 381 start-page: 1718 year: 2019 ident: ref_6 article-title: Nintedanib in progressive Fibrosing interstitial lung diseases publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1908681 – volume: 27 start-page: 929 year: 2022 ident: ref_14 article-title: Treatable traits in the NOVELTY study publication-title: Respirology doi: 10.1111/resp.14325 – volume: 24 start-page: 251 year: 2023 ident: ref_9 article-title: Walking the path of treatable traits in interstitial lung diseases publication-title: Respir. Res. doi: 10.1186/s12931-023-02554-8 – volume: 20 start-page: 57 year: 2019 ident: ref_3 article-title: The natural history of progressive fibrosing interstitial lung diseases publication-title: Respir. Res. doi: 10.1186/s12931-019-1022-1 – volume: 205 start-page: e18 year: 2022 ident: ref_28 article-title: Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline publication-title: Am. J. Respir. Crit. Care Med. doi: 10.1164/rccm.202202-0399ST – ident: ref_24 doi: 10.3390/jcm9041081 – volume: 130 start-page: 104934 year: 2019 ident: ref_26 article-title: A comparison of linear regression, regularization, and machine learning algorithms to develop Europe-wide spatial models of fine particles and nitrogen dioxide publication-title: Environ. Int. doi: 10.1016/j.envint.2019.104934 – volume: 384 start-page: 325 year: 2021 ident: ref_7 article-title: Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2008470
SSID	ssj0000913814
Score	2.288464
Snippet	Different factors, not limited to the lung, influence the progression of ILDs. A “treatable trait” strategy was recently proposed for ILD patients as a... Different factors, not limited to the lung, influence the progression of ILDs. A "treatable trait" strategy was recently proposed for ILD patients as a...
SourceID	doaj proquest gale pubmed crossref
SourceType	Open Website Aggregation Database Index Database Enrichment Source
StartPage	1047
SubjectTerms	Airway management Asthma Cardiology Chronic obstructive pulmonary disease Clinical outcomes Comorbidity Connective tissue diseases Cough Development and progression Emphysema endotypes Genotype & phenotype interstitial lung diseases Kinases Lung diseases Medical prognosis Patients Pharmaceutical industry phenotypes Population studies Precision medicine Quality of life Respiratory diseases Respiratory failure Sarcoidosis treatable traits Treprostinil
SummonAdditionalLinks	– databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagcIAD70egICMhcbKaxNnYPqEWWHGoqh5aqZwsP9FKVbJsUvr3mXG8oQUEB2552JGjefizPfMNIW9jJQ0ggcDa6D1r4JZZE2oG62WvAFDEOibK_ENxdCTPztRx3nAbcljl1icmR-17h3vkexyJRZAvXb1ff2NYNQpPV3MJjZvkFrIk1Cl073jeY0HOS1k1U8Ych9X93pTTns6sh6pGhcS6KldmpETc_7t7_gV0pslnef9_h_2A3Muwk-5PevKQ3AjdI3L3ChnhY3K5XAESpBMip32kAA0pMjyZlJdEzUgPTEpfh-vO01RdnFbsC9gKXYI69ZfsdI0dTxCIYkoWXJnVONBVR9POI8YlgL7TQ_Aw9ON0NDQ8IafLTycfPrNcloE5QFcjs0EakGnluAL4JkxlWhO8s8HKlnsrS1PK4FvLLXgPBwYO_hZQWOOEUkFFzp-Sna7vwnNC_aLhXvjYtFY1NUyTpROxNb4KrVqURhaEb0WjXeYsx9IZ5xrWLihQ_SeBFoTNvdYTZ8c_2h-g1Oe2yLidHvSbrzobsDZV9MiuJ4K0DXhFY3m74LWwpW0EwKCCvEOd0egXYIjO5PQG-FFk2NL7QsHcAgB6UZDday3Bnt3111tN0tmfDPqnGhXkzfwae2KMXBf6C2zTllwAoIaxPJu0df4lLgXgwlK9-PvHX5I7NYC2KaBzl-yMm4vwitx238fVsHmdjOsHHL0twQ priority: 102 providerName: ProQuest
Title	First Report of the Prevalence at Baseline and after 1-Year Follow-Up of Treatable Traits in Interstitial Lung Diseases
URI	https://www.ncbi.nlm.nih.gov/pubmed/38791009 https://www.proquest.com/docview/3059404369 https://www.proquest.com/docview/3060373521 https://doaj.org/article/a1fd10047e8b4301ab365327b0b47241
Volume	12
WOSCitedRecordID	wos001232395300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: Directory of Open Access Journals (DOAJ) customDbUrl: eissn: 2227-9059 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913814 issn: 2227-9059 databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2227-9059 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913814 issn: 2227-9059 databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2227-9059 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913814 issn: 2227-9059 databaseCode: M7P dateStart: 20130101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2227-9059 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913814 issn: 2227-9059 databaseCode: BENPR dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2227-9059 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000913814 issn: 2227-9059 databaseCode: PIMPY dateStart: 20130101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB7atIf2UPqu23RRodCTiG15LemYbbO0kC5LSWBzMnoZFoo3xE7y9zMjOcumLeTSm9eWQPK8Pq1nvgH43BbKIBIIvG695xX-5NaEkuN52WsEFG3ZRsr8Y7lYqNVKL3dafVFOWKIHTi_uwBStJ1YzGZStUBuNFfVUlNLmtpJlLFkvc6l3DlPRB-sCQ1GVauUEnusPUjV7_FrdFyWpInVU2YlFkbL_b8f8B9yMYWf-HJ6NeJEdpnW-gAehewlPd1gEX8H1fI0QjiUozTYtQ0zHiJrJxIIiZgY2M7HuHK87z2JbcFbwM1RyNkc92Fzz03OaeEIIkmqp8Mqsh56tOxb_MqSEAlRUdoyugX1L33T613A6Pzr5-p2P_RS4Q1g0cBuUQWEUTmjEXdIUpjbBOxusqoW3Kje5Cr62wqLZO7RMdJQInyontQ66FeIN7HWbLrwD5qeV8NK3VW11VWJ8y51sa-OLUOtpblQG4vbNNm4kG6eeF78bPHSQPJp_ySMDvp11nsg27hk_I6FtxxJVdryBCtSMCtTcp0AZfCGRN2TQuERnxroE3ChRYzWHUmNQQOQ7zWD_zkg0RHf38a3SNKMj6BtBfDhE868z-LR9TDMpua0Lm0saU-dCIhLGtbxNyrbdklASAV2u3_-PrX6AJyVispSvuQ97w8Vl-AiP3dWw7i8m8FCu1AQezY4Wy1-TaE8TSoVd4r3lj5_LsxsiiyOP
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB5VKRJw4P0IFFgkEKdVba_j9R4QailRo6ZRDqnUnsy-jCIhO8QuEX-K38iM7YQWEJx64ObE62jX-Wb2m92dbwBe5WGqkQl4nuTO8Rg_cqN9xDFedgoJRR7ljWT-WE4m6empmm7B93UuDB2rXPvExlG70tIa-a4gYRHSS1fvFl84VY2i3dV1CY0WFkf-2wpDturt6AD_39dRNPwwe3_Iu6oC3CI5qLnxqcYuhVYoZB9ShzrR3lnjTZoIZ9JAB6l3iREGwW8Rn-gukETEVirlVU4LoOjyt2MCew-2p6Pj6dlmVYdUNtMwbnP0hFDBbptF3-ySV2FEJkCVXC7MgU2pgN8nhF9objPdDW__by_qDtzqiDXbay3hLmz54h7cvCC3eB9WwzlyXdbGHKzMGZJfRhpWusm8Yrpm-7pJ0MfrwrGmfjoL-RmOhg3RYMoVP1nQgzOi2pR0hld6XldsXrBmbZVOXqBFszH6UHbQbn5VD-DkSkb-EHpFWfjHwNwgFk66PE6MiiMkAoGVeaJd6BM1CHTaB7GGQmY7VXYqDvI5w-iMAJT9CUB94JunFq0qyT_a7xPKNm1JU7z5olx-yjoXlekwd6QfKH1qYvT72ohkICJpAhNLJHp9eEMYzcjzYRet7hI4cKCkIZbtSYWzJ4YIgz7sXGqJHstevr1GbtZ5zCr7Cds-vNzcpifpFGDhy3NqkwRCYsiAfXnUWsdmSCKVyHwD9eTvP_4Crh_OjsfZeDQ5ego3IqSo7fHVHejVy3P_DK7Zr_W8Wj7vTJvBx6s2kh9QK4yc
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB5VKUJw4P0IFFgkEKdVbK_j9R4QagkWUUOUQyu1J7Mvo0jIDnFKxF_j1zFjO6EFBKceuNnxbrRrz8x-szvzDcCLIkw1IgHPk8I5HuMtN9pHHP1lpxBQFFHRUOZP5HSanpyo2Q583-TCUFjlxiY2htpVlvbIB4KIRYgvXQ2KLixiNsreLL5wqiBFJ62bchqtiBz6b2t03-rX4xF-65dRlL07evuedxUGuEWgsOLGpxqHF1qhEIlIHepEe2eNN2kinEkDHaTeJUYYVASLsoqmAwFFbKVSXhW0GYrmfxcheRz1YHc2_jA73e7wEONmGsZtvp4QKhi0GfXNiXkdRqQOVNXl3HrYlA34fXH4BfI2S192839-abfgRge42X6rIbdhx5d34Po5Gsa7sM7miIFZ64uwqmAIihlxW-kmI4vpFTvQTeI-XpeONXXVWchPcTYsQ0Wq1vx4QR2PCIJTMhpe6fmqZvOSNXuuFJGBms4maFvZqD0Uq-_B8aXM_D70yqr0D4G5YSycdEWcGBVHCBACK4tEu9AnahjotA9iIxa57djaqWjI5xy9NhKm_E_C1Ae-7bVo2Ur-0f6AJG7blrjGmx-q5ae8M125DgtHvILSpybG9UAbkQxFJE1gYokAsA-vSF5zsog4RKu7xA6cKHGL5ftS4aqKrsOwD3sXWqIlsxcfb6Q47yxpnf8U4T483z6mnhQdWPrqjNokgZDoSuBYHrSasp2SSCUi4kA9-vufP4OrqBn5ZDw9fAzXIkSubVTrHvRWyzP_BK7Yr6t5vXzaaTmDj5etIz8AP6uVXA
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=First+Report+of+the+Prevalence+at+Baseline+and+after+1-Year+Follow-Up+of+Treatable+Traits+in+Interstitial+Lung+Diseases&rft.jtitle=Biomedicines&rft.au=Amati%2C+Francesco&rft.au=Stainer%2C+Anna&rft.au=Maruca%2C+Giacomo&rft.au=De+Santis%2C+Maria&rft.date=2024-05-01&rft.pub=MDPI+AG&rft.issn=2227-9059&rft.eissn=2227-9059&rft.volume=12&rft.issue=5&rft_id=info:doi/10.3390%2Fbiomedicines12051047&rft.externalDocID=A795380455
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2227-9059&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2227-9059&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2227-9059&client=summon